Merck & Co. Inc. (MRK) News

Merck & Co. Inc. (MRK): $125.23

0.14 (-0.11%)

POWR Rating

Component Grades








Add MRK to Watchlist
Sign Up

Filter MRK News Items

MRK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MRK News Highlights

  • For MRK, its 30 day story count is now at 21.
  • Over the past 13 days, the trend for MRK's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • The most mentioned tickers in articles about MRK are DRUG, DOW and EC.

Latest MRK News From Around the Web

Below are the latest news stories about MERCK & CO INC that investors may wish to consider to help them evaluate MRK as an investment opportunity.

5 Biggest Lawsuits in 2023 That Could Hit Your Wallet

From the resumption of student loan repayments to charges against the world's largest cryptocurrency exchange, several 2023 court cases could affect consumers.

Yahoo | December 28, 2023

Merck & Co., Inc. (NYSE:MRK) Shares Could Be 50% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, Merck fair value estimate is US$215 Merck is estimated to be...

Yahoo | December 28, 2023

20 Most Expensive Drugs in the World

In this article, we will take a look at the 20 most expensive drugs in the world. If you want to skip our discussion on the pharmaceutical industry, you can go directly to the 5 Most Expensive Drugs in the World. The health of the global population is being adversely affected due to numerous factors, […]

Yahoo | December 27, 2023

Rethinking Immunotherapy for Cancer: When Is the Best Time to Stop?

Immune-boosting drugs extend cancer patients’ lives and deliver billions in sales to drugmakers, but some patients might be getting more of the drugs than they need.

Yahoo | December 26, 2023

January Effect: 3 Under-the-Radar Stocks Poised for a New Year Jump

Are you looking to profit from the January effect?

Yiannis Zourmpanos on InvestorPlace | December 24, 2023

7 Small-Cap Stocks That Wall Street Loves for Good Reason 

The market rally is showing signs of broadening to include small-cap stocks, here are seven that analysts are upgrading

Chris Markoch on InvestorPlace | December 22, 2023

12 Best Undervalued Stocks to Buy According to Reddit

In this article, we discuss the 12 best undervalued stocks to buy according to Reddit. If you want to read about some more undervalued stocks, go directly to 5 Best Undervalued Stocks to Buy According to Reddit. Retail investors who often discuss their investment strategies on platforms like Reddit have become a dominant market force […]

Yahoo | December 22, 2023

Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

BASKING RIDGE, N.J. & RAHWAY, N.J., December 22, 2023--Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more

Yahoo | December 22, 2023

7 Best Dow Jones Stocks to Buy for Conservative Investors

With the Federal Reserve seemingly open to the idea of interest rate cuts next year, the narrative for the best Dow Jones stocks for conservative investors appears overly cautious.

Josh Enomoto on InvestorPlace | December 21, 2023

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Receive Public Listing for Patients with Advanced Endometrial Carcinoma (EC) that is not MSI-H or dMMR

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai announce that KEYTRUDA®, Merck's anti-PD-1 therapy, plus LENVIMA®, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, is now reimbursed with clinical criteria and conditions under the British Columbia, Alberta, Saskatchewan, Ontario, Quebec, Nova Scotia, New Brunswick, and Newfoundland drug plans, for adult patients with advanced endometrial carcinoma (EC) that is not microsatellite

Yahoo | December 21, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!